Jeffrey Hessekiel Sells 25,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 25,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the sale, the executive vice president now directly owns 605,325 shares of the company’s stock, valued at approximately $15,968,473.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jeffrey Hessekiel also recently made the following trade(s):

• On Monday, August 26th, Jeffrey Hessekiel sold 20,000 shares of Exelixis stock. The stock was sold at an average price of $25.79, for a total value of $515,800.00.

Exelixis Stock Down 1.1 %

Shares of Exelixis stock opened at $25.96 on Friday. Exelixis, Inc. has a 12-month low of $18.64 and a 12-month high of $27.83. The stock has a 50 day moving average price of $25.56 and a two-hundred day moving average price of $23.48. The stock has a market capitalization of $7.41 billion, a P/E ratio of 40.56, a PEG ratio of 0.56 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.44. The business had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. Sell-side analysts anticipate that Exelixis, Inc. will post 1.59 earnings per share for the current year.

Institutional Investors Weigh In On Exelixis

Several hedge funds and other institutional investors have recently made changes to their positions in EXEL. Fisher Asset Management LLC lifted its position in shares of Exelixis by 232.6% during the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares during the last quarter. Rise Advisors LLC bought a new position in Exelixis in the 1st quarter worth approximately $28,000. Park Place Capital Corp acquired a new position in shares of Exelixis during the second quarter worth approximately $45,000. GAMMA Investing LLC boosted its position in shares of Exelixis by 107.9% in the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 1,041 shares during the period. Finally, EntryPoint Capital LLC grew its stake in shares of Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,746 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, September 18th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Exelixis in a research note on Tuesday, July 30th. Royal Bank of Canada reiterated an “outperform” rating and set a $27.00 price objective on shares of Exelixis in a report on Thursday. Finally, JMP Securities restated a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Friday, September 20th. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.